XERS Xeris Pharmaceuticals Inc

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations.

As of 06/24/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  135,530,756
Average volume:  2,110,449
Market cap:   $239,889,438
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLR7H87
Valuation   (See tab for details)
PE ratio:   -1.60
PB ratio:   2.29
PS ratio:   3.77
Return on equity:   -143.10%
Net income %:   -216.74%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy